Literature DB >> 30916629

Clustering of Patients with Interstitial Cystitis/Bladder Pain Syndrome and Chronic Prostatitis/Chronic Pelvic Pain Syndrome.

H Henry Lai1, James H L Thu2, Frederick V Moh2, Alethea Paradis2, Joel Vetter2.   

Abstract

PURPOSE: We performed clustering analysis of patient symptoms to discover common patient subtypes in females and males with interstitial cystitis/bladder pain syndrome or chronic prostatitis/chronic pelvic pain syndrome.
MATERIALS AND METHODS: The clinical variables included in k-means clustering were urological pain severity, urinary urgency, frequency and nonurological pain, each on a 0 to 10 numerical rating scale, and a yes or no response to each of the 6 UPOINT (Urological Treatment Program for Chronic Prostatitis) domains, including the urinary, psychosocial, organ specific, infection, neurological/systemic and skeletal muscle tenderness domains.
RESULTS: Included in study were 211 patients seeking care of interstitial cystitis/bladder pain syndrome or chronic prostatitis/chronic pelvic pain syndrome. The k-means clustering algorithm identified 3 clusters of patients with interstitial cystitis/bladder pain syndrome and chronic prostatitis/chronic pelvic pain syndrome, including 1) a mild pelvic symptom cluster in about 30% of patients, 2) a severe pelvic symptom cluster in about 40% and 3) a systemic symptom cluster in about 30%. Patients in the systemic cluster were younger by about 5 to 7 years and more likely to be female. They had the most severe urinary symptoms (urgency, frequency and painful bladder filling), and the most severe pelvic and nonpelvic pain. They were also more likely to have chronic overlapping pain conditions, psychosocial issues (depression, anxiety and somatic symptoms) and poorer quality of life than patients in the 2 other pelvic clusters. They were not less likely to have Hunner lesions in the bladder.
CONCLUSIONS: Symptom based clustering identified 3 clusters of patients with interstitial cystitis/bladder pain syndrome and chronic prostatitis/chronic pelvic pain syndrome. These patient subtypes had different pelvic and systemic presentations. Patients in the systemic cluster may benefit from interdisciplinary therapies. Future studies are needed to elucidate differences in pathophysiology among these clusters.

Entities:  

Keywords:  cluster analysis; cystitis; interstitial; prostate; prostatitis; urinary bladder

Mesh:

Year:  2019        PMID: 30916629     DOI: 10.1097/JU.0000000000000250

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  4 in total

Review 1.  Preclinical models of endometriosis and interstitial cystitis/bladder pain syndrome: an Innovative Medicines Initiative-PainCare initiative to improve their value for translational research in pelvic pain.

Authors:  Paulina Nunez-Badinez; Bianca De Leo; Alexis Laux-Biehlmann; Anja Hoffmann; Thomas M Zollner; Philippa T K Saunders; Ioannis Simitsidellis; Ana Charrua; Francisco Cruz; Raul Gomez; Miguel Angel Tejada; Stephen B McMahon; Laure Lo Re; Florent Barthas; Katy Vincent; Judy Birch; Jane Meijlink; Lone Hummelshoj; Patrick J Sweeney; J Douglas Armstrong; Rolf-Detlef Treede; Jens Nagel
Journal:  Pain       Date:  2021-09-01       Impact factor: 6.961

2.  Can We Use Urinary Cytokine/Chemokine Analysis in Discriminating Ulcer-Type Interstitial Cystitis/Bladder Pain Syndrome?

Authors:  Yuan-Hong Jiang; Jia-Fong Jhang; Hann-Chorng Kuo
Journal:  Diagnostics (Basel)       Date:  2022-04-27

3.  Dysmenorrhea subtypes exhibit differential quantitative sensory assessment profiles.

Authors:  Kevin M Hellman; Genevieve E Roth; Katlyn E Dillane; Ellen F Garrison; Folabomi A Oladosu; Daniel J Clauw; Frank F Tu
Journal:  Pain       Date:  2020-06       Impact factor: 7.926

4.  Prostatic fluid exosome-mediated microRNA-155 promotes the pathogenesis of type IIIA chronic prostatitis.

Authors:  Baixiong Zhao; Jun Zheng; Yang Qiao; Yongquan Wang; Yang Luo; Dinglin Zhang; Qiyan Cai; Yang Xu; Zhansong Zhou; Wenhao Shen
Journal:  Transl Androl Urol       Date:  2021-05
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.